REVELATION BIOSCIENCES, INC. (REVB) Form 8-K — Jun 24, 2026
Revelation Biosciences announced that stockholders approved a proposal granting the Board discretionary authority to effect a reverse stock split of the company's common stock at a ratio ranging from 1-for-2 to 1-for-250 within the next year. This authority is often utilized by small-cap companies to maintain compliance with minimum bid price listing requirements on Nasdaq. The company also entered into amended employment agreements with CEO James Rolke and CFO Chester S. Zygmont, increasing change-in-control severance benefits to two times the sum of base salary and target bonus.
Key figures
- Shares outstanding
- 3908420
- Severance multiplier
- 2
- Votes for reverse split
- 1786623
- Reverse split ratio range
- 1-for-2 to 1-for-250
- Severance coverage months
- 18
- Director election votes for
- 519169
- Votes abstain reverse split
- 3410
- Votes against reverse split
- 444315
- Director election votes against
- 24779
- Director election votes withheld
- 263081
Price after filing
Close on the filing date to close N calendar days later (from $1.03). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.